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Background: The global prevalence of type 2 diabetes is increasing. Effective strategies to address this public
health challenge are currently lacking. A number of epidemiological studies have reported associations between
low concentrations of 25-hydroxy vitamin D and the incidence of diabetes, but a causal link has not been
established. We investigate the effect of vitamin D supplementation on the metabolic status of individuals at
increased risk of developing type 2 diabetes.
Methods/design: In a randomised double-blind placebo-controlled trial individuals identified as having a high risk
of type 2 diabetes (non-diabetic hyperglycaemia or positive diabetes risk score) are randomised into one of three
groups and given 4 doses of either placebo, or 100,000 IU Vitamin D2 (ergocalciferol) or 100,000 IU Vitamin D3
(cholecalciferol) at monthly intervals. The primary outcome measure is the change in glycated haemoglobin level
between baseline and 4 months. Secondary outcome measures include blood pressure, lipid levels, apolipoproteins,
highly sensitive C-reactive protein, parathyroid hormone (PTH) and safety of supplementation. and C-reactive
protein. The trial is being conducted at two sites (London and Cambridge, U.K.) and a total of 342 participants are
being recruited.
Discussion: Trial data examining whether supplementation of vitamin D improves glycaemic status and other
metabolic parameters in people at risk of developing type 2 diabetes are sparse. This trial will evaluate the causal
role of vitamin D in hyperglycaemia and risk of type 2 diabetes. Specific features of this trial include recruitment of
participants from different ethnic groups, investigation of the relative effectiveness and safety of vitamin D2 and D3
and an evidence based approach to determination of the dose of supplementation.
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The number of people with diabetes is increasing across
the world, with the latest estimates from the International
Diabetes Federation predicting a rise from 366 million in
2011 to 552 million in 2030 [1]. The clinical consequences
of type 2 diabetes (T2D) including macrovascular and
microvascular disease, and related premature mortality [2]
make it a condition of major public health importance. As
such, the identification of risk factors for T2D, particularly
those that might be potentially modifiable, is of great
interest.
There is convincing evidence that changes to diet and
physical activity can help to prevent or delay the onset
of T2D among those at high risk [3-6]. However, inten-
sive lifestyle modification interventions are difficult to
sustain and costly to implement. Thus, there is interest
in identifying complementary strategies that might help
in the prevention of T2D. There is accumulating evidence
that vitamin D insufficiency is associated with the risk
of developing T2D [7-9]. Whether supplementation of
vitamin D can delay or prevent T2D is unknown.
Epidemiological studies have examined the association
between dietary vitamin D intake and the risk of diabetes
[10,11], but these omitted information on the major non-
dietary component of vitamin D from endogenous synthe-
sis through sun exposure. Circulating 25-hydroxyvitamin
D (25[OH]D) concentration is the best indicator of vita-
min D status as it accounts for both vitamin D intake and
endogenous synthesis [12]. More recent epidemiological
studies have examined the association between circulating
25(OH)D concentrations and incident diabetes, and the
findings have been largely consistent, demonstrating an in-
verse association. Such findings have been summarised in
systematic reviews and meta-analyses [7-9], with the latest
one from our group showing a 41% (95% confidence inter-
val 33% to 48%) lower risk for those in the highest versus
the lowest quartile of 25(OH)D [7]. Whilst meta-analysis
deals with issues of consistency and precision, it does
not resolve the problems of confounding and selection
bias in observational studies. To address the question of
whether observed associations between vitamin D and
risk of T2D are causal in nature, there is a need to con-
duct randomised controlled trials of supplementation.
Two clinical trials that examined incident diabetes as an
outcome found no effect of supplementation with 400 IU/
day and 800 IU/day of vitamin D respectively [13,14]. In
the larger of these trials (the Women’s Health Initiative
randomised controlled trial), there was no association
between vitamin D supplementation (in combination with
calcium supplementation) and T2D incidence (hazard
ratio 1.01, 95% CI: 0.94; 1.10) [13]. A causal link could
not be ruled out by this trial, however, as it tested a low
dose of 400 IU/day of vitamin D3 [15]. In two separate
systematic reviews, Mitri and Pittas et al. synthesisedthe available evidence on clinical trials of the effect of
vitamin D supplementation on diabetes incidence (8 trials)
or intermediate outcomes such as levels of glycaemia (11
trials) [8,9]. Overall, few were considered of good quality,
but there was no overall benefit of supplementation with
vitamin D. Of five trials measuring insulin resistance as an
outcome [8], only one in New Zealand among vitamin D
deficient (25(OH)D< 50 nmol/l) South Asian women
reported significant improvement assessed by homeostasis
model assessment [16]. More recently, Pittas’ group in-
vestigated whether vitamin D supplementation, with or
without calcium, improved glucose homeostasis in
adults at high risk of diabetes [17]. They included 92
adults (mean BMI 32 kg/m2, mean glycated haemoglobin
of 5.9% (41 mmol/mol)) who were randomly assigned in a
2-by-2 factorial-design trial, to receive either cholecalcif-
erol (2000 IU once daily) or calcium carbonate (400 mg
twice daily) for 16 weeks. They reported improved beta
cell function in the vitamin D supplemented group with
increased glucose disposition index and improved insulin
secretion. There was no significant effect on glycated
haemoglobin (HbA1c) level, although there was a tendency
toward greater attenuation in the rise in HbA1c over fol-
low up. There was also no significant effect of calcium
supplementation. Two further trials have since been pub-
lished showing no associations between supplementation
with relatively high dose vitamin D and markers of insulin
sensitivity [18,19]. These trials were restricted to minority
groups (Latin Americans or African Americans) or
women, and a common feature was the successful increase
in 25(OH)D level following D3 supplementation. In the
Davidson et al. study [18], there was also no effect on dia-
betes incidence, but follow up was short at 12 months.
However, at 12 months, HbA1c levels were significantly
lower in the vitamin D group compared with the placebo
group. Taken together, the evidence to date from trials is
suggestive but not conclusive, and there is further need
for well-designed trials, with adequate sample size, ad-
equate dose of supplementation and good adherence, to
advance this field of enquiry. Three particular issues are of
further interest. The first relates to the dose of supplemen-
tation. Recent Institute of Medicine (IOM) guidelines
suggested that the vitamin D needs of at least 97.5% of
the population would be met by a recommended dietary
allowance (RDA) of 600 IU/day for adults aged up to 70,
and 800 IU/day after the age of 71 years [20]. IOM also
raised the safe limit of vitamin D intake to 4000 IU/day
and suggested that a serum concentration of 50 nmol/l
is sufficient for most people [21]. However, several
authors have suggested that IOM recommendations
are focussed on bone health alone, do not account for
potential extra-skeletal effects and are therefore too
conservative [22]. A growing body of evidence suggests
that larger doses than those previously investigated
Menon et al. BMC Public Health 2013, 13:999 Page 3 of 11
http://www.biomedcentral.com/1471-2458/13/999(equivalent to 2,000 IU – 10,000 IU daily) are required
to optimise vitamin D status [15].
A second issue relates to whether vitamin D2 (ergo-
calciferol) or vitamin D3 (cholecalciferol) is likely to be
more effective, or whether they would have equivalent
effects on glycaemia. Previously thought to be equipo-
tent in elevating serum 25(OH)D, several studies now
suggest that vitamin D2 is less effective than vitamin D3
[23-27]. In contrast, a trial by Hollis et al. reported that
vitamin D2 and D3 were equivalent in their ability to
maintain circulating levels of 25(OH)D over 11 weeks of
supplementation [28]. Most recently, based on a meta-
analysis of clinical trials that directly compared the 25
(OH)D raising effects of supplementation with D2 or
D3, Tripkovic et al. concluded that D3 supplementation
is more efficacious [29]. However, according to the free
hormone hypothesis, despite being less efficacious in
elevating total 25(OH)D levels, 25(OH)D2 may be more
available to exert biological activity being less tightly
protein bound than 25(OH)D3. However, the effects of
factors such as hydroxylation rates and deactivation of
D2 and D3 on biological activity are unclear, and no trial
has yet reported on the comparative effects of D2 and
D3 on glycaemia.
A further issue relates to the effectiveness of vitamin D
supplementation in people from different ethnic groups.
Melanin in the skin reduces vitamin D production and
hence the darker the skin pigmentation, the lower the syn-
thesis of vitamin D for equivalent sun exposure [30]. In a
study in the United States, researchers exposed healthy
young individuals from different races to similar doses of
UVB rays and measured the 25(OH)D concentrations
before and after exposure. Baseline concentrations were
similar, but Caucasians had highest concentrations of 25
(OH)D following UVB exposure, followed by East Asians,
South Asians and Blacks [31]. Concentrations of 25(OH)D
in Hispanics and African-Americans are lower than those
among the Caucasians [32]. Ethnic groups in the UK such
as the South Asian population, have especially high rates
of hypovitaminosis D [33-35]. It is therefore important to
examine the effectiveness of vitamin D supplementation
on levels of glycaemia among people of different ethnic
groups in the same study, to add to the literature on this
topic [16,18,19,36].
We aim to address these unresolved issues, especially
concerning the nature of the association between vitamin
D and metabolic parameters among people at risk of dia-
betes. We particularly wanted to include men and women
of different ethnic groups, evaluate effects of an adequate
dose of supplementation, and test the relative efficacy of
vitamin D2 and D3 versus placebo among those at elevated
risk of diabetes. The results obtained should provide high
quality scientific evidence to improve understanding, and
will also help to inform the conduct of larger trials withdisease end points such as diabetes and cardiovascular
disease.
Objectives
The primary objective of this trial is to determine whether
oral supplementation with vitamin D2 or vitamin D3 can
lead to reduction in glycaemia and an improvement in re-
lated metabolic abnormalities in people at risk of develop-
ing diabetes.
The secondary objectives of this trial are (i) to examine
the feasibility and acceptability of vitamin D supplementa-
tion to inform the design of a future RCT with diabetes
and/or cardiovascular endpoints, and (ii) to compare the
efficacy of vitamin D2 and vitamin D3.
Sponsors
The trial is jointly sponsored by Queen Mary University of
London and the Medical Research Council Epidemiology
Unit at Cambridge. Trial funding is from a block grant
from the NHS Tower Hamlets and from MRC Epidemi-
ology Unit core funding (MC_UP_A100_1003).
Methods/design
We designed a double-blind, placebo-controlled randomised
clinical trial amongst people at risk of developing T2D,
across two sites - East London and Cambridge, UK. We
are randomly allocating 342 participants to one of three
groups, to receive a monthly dose for four months, of
100,000 IU (equivalent to 2.5 mg) of either cholecalciferol
(vitamin D3) or ergocalciferol (vitamin D2) or a monthly
dose of placebo (miglyol oil). Each participant is followed-
up for a total of 4 months from their first visit. The inclu-
sion and exclusion criteria of the trial are as follows.
Inclusion criteria
Men and women aged 30–75 years, from any ethnic
group, who can provide informed consent for participa-
tion in the trial and are at a high risk of developing type
2 diabetes are included.
Risk of developing diabetes is defined by the following
criteria:
A. Non-diabetic hyperglycaemia; either impaired
glucose tolerance (IGT) or impaired fasting glucose
(IFG) as defined by current World Health
Organisation (WHO) criteria [37], or HbA1c
between 5.5% and 6.49% (equivalent to 37 to 47
mmol/mol), where this information is available in
medical records (London), or in the records of
studies in which the participants have consented to
being re-approached to consider participating in
future studies (Cambridge), or,
B. Cambridge Risk Score (CRS) [38-41] cut offs that
indicate increased risk for diabetes. The CRS cut-offs
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for South Asians and 0.199 for Caucasians [39]. For
other groups the cut-off for Caucasians is used. This
approach is used at the London site.
Exclusion criteria
Participants are excluded if they have a known history of
diabetes or have used oral hypoglycaemic agents, have
random blood glucose during initial screening >11 mmol/l,
have known intolerance to vitamin D2 or D3 within the
previous two months or are currently using vitamin D
supplements, have a known history of hypercalcaemia
(serum calcium >2.65 mmol/l) or point of care ionised
calcium >1.3 mmol/l. They are also excluded if they have
known stage 4 or worse chronic kidney disease (eGFR
(estimated glomerular filtration rate) < 30 ml/min), a
history of significant liver disease (AST (aspartate amino-
transferase) >3 x upper limit of normal (ULN) or ALT
(Alanine aminotransferase) >3 x upper limit of normal
(ULN) or serum bilirubin > 2.5 x ULN), a known history
of renal stones, hyperparathyroidism, active sarcoidosis,
tuberculosis or malignancy (active defined as currently on
treatment and/or medication for the above conditions),
have taken cardiac glycosides or oral/ intramuscular/
intravenous corticosteroids (excluding inhaled and topical
corticosteroids) in the past one month. They are excluded if
they have known current anaemia (haemoglobin <11 g/dL)
or haemoglobinopathy such as sickle cell anaemia and
beta or alpha thalassemia. Additionally, if they plan to
travel out of the London or Cambridge area (depending
on site of recruitment) within 8 weeks of enrolment such
that it would disrupt monitoring of the participant, they
are excluded. Among women, current breast feeding,
pregnancy or planning a pregnancy are also considered
exclusion criteria.
Outcomes
The primary endpoint of the trial is HbA1c. There are
multiple secondary endpoints including systolic and
diastolic blood pressure, random cholesterol, HDL chol-
esterol, ApoA1 and ApoB apolipoproteins, CVD risk
score as assessed by the UKPDS risk engine (version 2)
[42] and additionally in London only, a measurement of
arterial stiffness assessed by pulse wave velocity. Further
secondary endpoints include anthropometry (waist cir-
cumference and body mass index) and serum concen-
trations of C-reactive protein (measured using a high
sensitivity assay), fructosamine, and parathyroid hormone.
Other endpoints include the safety of oral vitamin D with-
out a pre-assessment of vitamin D status, the proportion
of participants with a serum 25(OH)D in categories
of <25, 25 to <50, 50 to <75, 75 to <150 and greater
than or equal to 150 nmol/L measured by an LC-MS/MS
(liquid chromatography–tandem mass spectrometry) assay,and the feasibility and acceptability of the intervention.
The trial also assesses functional status (SF-8), health util-
ity (EQ-5D) and total body pain (BPI).
Intervention
In this trial the dose of vitamin D being used is 100,000 IU
(equivalent to 2.5 mg) per month administered as four
oral doses over consecutive months. The two investiga-
tional medicinal products (IMP) include cholecalciferol
(prepared as Vigantol oil containing 20,000 IU vitamin D3
per ml in Miglyol vehicle oil), or ergocalciferol (prepared
as Sterogyl containing 20,000 IU vitamin D2 per ml in
ethanol). In the active intervention groups this repre-
sents a daily dose equivalent of ~3,300 IU. The placebo
is Miglyol 812 oil with esters of coconut and palm-
derived oils.
We chose the oral route of administration as this is
the most commonly used in clinical practice, and it re-
sults in less inter-individual variability in achieved serum
25(OH)D concentrations compared to the intramuscular
route [43]. It is also the route used by other investigators
in studies which show safety of the dosage regimen used
in this trial [44,45].
Investigational medicinal products
Vigantol oil (cholecalciferol) is manufactured by Merck
Serono GmbH in the Federal Republic of Germany at
a licensed site under GMP (Good Manufacturing Practices,
WHO) conditions. Sterogyl (ergocalciferol) is manufactured
by DB Pharma in France at a licensed site, also under
GMP conditions. The placebo (‘Miglyol oil’), which is also
the vehicle for vitamin D3 in Vigantol oil does not contain
any pharmacologically active ingredient. The investiga-
tional agents are repackaged into randomisation packs by
a commercial laboratory (Nova Laboratories).
Safety
The vitamin D investigational medicinal products used
in this trial have undergone safety and quality checks,
and are prescribed by a registered medical practitioner
in both study centres. We wanted to use an adequate
dose of vitamin D and after careful consideration opted
for a dose of 100,000 IU per month, in order to increase
the likelihood of generating a significant difference in vita-
min D status between the treatment and placebo groups.
There have been several trials in which high doses of vita-
min D were administered without any adverse events. In
an Indian randomised controlled trial, supplementation in
men with three doses of 120,000 IU of vitamin D at fort-
nightly intervals was not associated with any adverse
events in general or specifically relating to hypercalcaemia
[36]. In a Canadian trial, 4000 IU of vitamin D3 daily for
2–5 months in healthy adults did not result in any adverse
effects [46]. Two clinical studies of 10,000 IU/day have
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trations to the high end of normal concentrations with-
out inducing toxicity in healthy volunteers [44,45]. The
recent IOM (Institute of Medicine) aforementioned
review revised the safe dose of vitamin D upwards from
2000 IU/day to 4000 IU/d, which the dose we are
supplementing falls well within [21]. Side effects of
vitamin D supplementation are rare and include gastro-
intestinal symptoms (such as nausea, constipation, or
diarrhoea), hypercalcaemia, hypercalcuria and associ-
ated kidney stones. To minimise risk of hypercalcaemia
and hypercalcuria amongst predisposed individuals, we
exclude individuals with known sarcoidosis, malignancies
and tuberculosis. As a safety precaution, three measures
are recorded for all recruited participants at all trial visits:
a point of care ionised calcium test, a laboratory serum
corrected calcium test and a laboratory urinary calcium to
creatinine ratio test. Trial participants who have high
point of care ionised calcium (>1.3 mmol/L) or urine
calcium:creatinine ratio (molar ratio >1) or serum cor-
rected calcium > 2.65) are excluded from further doses
of the IMP, but continue to be followed up. Addition-
ally, provision has been made for the recording of ad-
verse events or reactions.
Recruitment
London site
Electronic searches of lists of patients in GP practices in
East London are done by the practice staff to identify
suitable participants. The Cambridge Risk Score (CRS)
[38-41] is used to identify participants who are at high
risk for T2D. In addition, a previous record of the pres-
ence of impaired glucose tolerance, impaired fasting
glucose or non-diabetic hyperglycaemia assessed by
HbA1c is used to identify potential eligible participants.
Practice staff extract information from the medical re-
cords on the following variables which comprise the
Cambridge Risk Score: age, sex, smoking status, family
history of diabetes, body mass index and whether the
patient is prescribed anti-hypertensive or steroid medica-
tion. In addition, they extract information on ethnicity.
Once identified, and after applying exclusion criteria that
can be accessed from medical records, potential partici-
pants receive a letter inviting them to participate in the
trial, a reply slip, a patient information sheet and a flyer
with contact information. Potential participants who reply
expressing an interest are telephoned by a member of the
study team to provide further information as required and
to arrange an appointment to attend a research centre.
Cambridge site
In Cambridge, participants are recruited from the Fenland
study, an on-going population-based observational study
investigating the influence of lifestyle and genetic factorson the development of diabetes, obesity, and other
metabolic disorders [47]. Residents of Cambridgeshire,
in the east of England, born between 1950 and 1975 are
potentially eligible to participate in the Fenland Study
and are excluded by their general practitioner if they
have been diagnosed with diabetes or a terminal illness
with a prognosis of less than one year, have a psychotic
illness, are pregnant or lactating, or if they are unable to
walk unaided. Approximately 28% of those registered
with participating general practices in the Cambridge-
shire Primary Care Trust have enrolled in the Fenland
Study (more than 8,000 participants). Fenland study
participants are eligible for this trial if they had agreed
to be contacted again to gauge interest in involvement
in future studies and do not meet the trial exclusion
criteria. Potential participants are mailed an invitation
letter for the trial, an information sheet and a flyer with
contact information. Those interested in taking part are
asked to complete the response form and to return it in
an enclosed freepost reply envelope. In the event of
non-response, a second mailing is sent approximately
four weeks after the first. Responders are excluded from
the trial if they have been diagnosed with diabetes or
are actively participating in another trial, or if any of the
trial exclusion criteria apply. For eligible participants,
telephone contact is made and any queries are addressed
before setting an invitation date for the baseline visit.
In Cambridge, HbA1c is primarily used as the eligibility
criterion for identifying increased risk of diabetes.
Randomisation and blinding
Randomisation into three groups (cholecalciferol (D3),
ergocalciferol (D2), or placebo) follows stratification of
participants on the basis of age (two groups 30–50 and
51–75 years) and sex (male and female) into four
groups, with a block size of 6 within each group.
In this double-blind trial, neither the participant, the in-
vestigators, nor the laboratory staff know whether partici-
pants have been allocated to vitamin D2, D3 or placebo
during the course of the study. Since the IMPs are oil
based or ethanol based products, in order not to com-
promise allocation concealment, the trial drug is admin-
istered by a person other than the investigator. The
participants are also asked not to let the investigator
know about any physical characteristics (including taste
and feel) of the product that they have consumed.
Trial procedures and follow-up
As shown in the Figure 1, each participant has a total
of 4 visits to the trial centre and one telephone call at 3
months to discuss the appropriateness of taking the
final of the four doses of IMP. The initial visit includes
informed consent, assessment of eligibility, administra-
tion of questionnaires regarding physical activity, diet,
Take blood samples.
Do anthropometric measurements (and PWV in London only).
Complete questionnaires.
Pre-trial
1st visit - Day1
2nd visit - 1 month 
3rd visit – 2nd month
3rd month
4th visit – 4th month
Electronic search in general practices to identify individuals at risk of developing 
T2D by using the Cambridge Risk Score or by a record of non-diabetic 
hyperglycaemia using HbA1c, impaired glucose tolerance or impaired fasting 
glucose.
Approach previous study volunteers who have provided consent to be re-
approached for future studies and who appear eligible for the current trial.
Invitation letter and information sheet to be posted or given at community centre
to potential participants. Enclose a return slip.
Contact participant after 7 days by telephone and invite them to a recruitment 
appointment at a practice or research facility.
Obtain informed consent and answer any queries.
Take ionised calcium, serum calcium, urine calcium:creatinine ratio and random 
blood glucose safety sample.
Ensure negative pregnancy result in women of childbearing age.
Do anthropometric measurements (including pulse wave velocity (PWV) in 
London only) and other blood samples.
Give participant 1st dose of investigational medicinal product (IMP)/placebo and 
information sheet with contact details. Set a date for next appointment.
Take safety samples (serum calcium – POC (point of care) test and urine Ca:Cr 
ratio).
Give participant 2nd dose of IMP/placebo.
Set a date for next appointment.
Telephone call reminder to take 4th dose of IMP/placebo
Take safety samples (serum calcium – POC test and urine Ca:Cr ratio).
Give participant 3nd dose of IMP/placebo.
Give participant 4th dose of IMP/placebo to take on 90th day.
Set a date for next appointment.
Figure 1 Trial visits and procedures for participants.
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brief pain inventory, randomisation and administration
of the first dose of study IMP. Subsequent visits (and
the telephone call) are at monthly intervals. Second
and third visits are for safety assessment and observa-
tion of consumption of the next two doses of the studyIMP, while the 4th (last) dose of the IMP is taken at
home prompted by a phone call from the trial staff, if
prior safety checks are within normal limits. The final
follow-up visit is at the end of 4 months, when ques-
tionnaires are repeated and a final set of blood samples
are collected.
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The trial team collects baseline blood samples from all
participants during the first visit, after informed con-
sent, to assess levels of serum ionised calcium as well as
serum 25(OH)D assay, HbA1c and the other secondary
endpoints mentioned earlier. During the second and
third visits blood samples are collected only for safety
analysis (as described under the section on safety) to
make a judgement about continuation of the IMP. During
the final (fourth) visit all blood samples are repeated, as
during the first visit. Assays for safety monitoring (serum
ionised calcium) at all visits are performed contemporan-
eously. For other trial endpoint assays, the HbA1c samples
from the first and fourth visit are analysed immediately on
fresh samples, while aliquots for all other assays (including
25(OH)D) are stored frozen at -70°C to be measured at
the end of the trial. Thus in summary, blood samples for
safety are collected at all four visits, while for other end-
points bloods are collected only at the first (baseline) and
fourth (final) visit.
HbA1c, the trial primary end-point is measured according
to IFCC (International Federation of Clinical Chemistry
and Laboratory Medicine) standards in both trial centres
(Royal London Hospital Biochemistry Laboratory for
East London and Addenbrookes Hospital Biochemistry
Laboratory for Cambridge). Results are reported in both
IFCC and DCCT units. Serum 25(OH)D measurement
is performed at Homerton University Hospital NHS
trust laboratory (London). This laboratory participates
in the DEQAS quality assurance scheme and measures
both 25(OH)D2 and D3 using the LC/MS/MS (liquid
chromatography/ mass spectrometry/mass spectrometry)
method which is well validated [48]. The other measure-
ments including parathyroid hormone, fructosamine, hsCRP
and lipid assays are also carried out at Homerton University
Hospital NHS Trust laboratory.
Sample size
Sample size calculations showed that 207 participants
(69 per randomised group) are required to detect a 0.2%
difference in mean HbA1c between the placebo and either
vitamin D2 or vitamin D3 groups (power calculation was
based on DCCT units) with 90% power and a 5% signifi-
cance level, assuming a standard deviation of HbA1c of
0.5%. However, given the importance of the secondary
endpoint systolic blood pressure (SBP), a further calcula-
tion was performed to estimate the sample size that would
be needed to detect a 5 mmHg difference in mean SBP be-
tween randomised groups, assuming a standard deviation
of 16 mmHg. The assumptions for the sample size cal-
culations were based on data from the ProActive trial
[49] and the BanglaDip Study (personal communica-
tion). This yielded a requirement of 339 participants
(113 in each group). Pragmatically, recruiting this largernumber of participants will also mean that the study
will still be powered for the primary endpoint (HbA1c)
even if there are losses to follow up. Because 339 is not
divisible by 6 (the block size for randomisation), the tar-
get number is 342 across the two test sites.
Statistical analysis plan
The analysis plan is available at http://www.mrc-epid.cam.
ac.uk/files/2013/04/VitDtrial_AnalysisPlan_Sep2012.pdf. In
brief, the primary analysis of efficacy endpoints uses an
Intention-To-Treat (ITT) population, which includes all
participants for whom outcome data are available, in
the group to which they were randomised, regardless of
the treatment actually received. A secondary analysis of
efficacy endpoints uses a Per-Protocol (PP) population.
This population excludes individuals who did not com-
ply with the protocol (e.g. individuals who did not take
all doses of the IMP). The analysis of safety endpoints
uses a safety population, which includes all participants
in the group based on treatment actually received. Any
individual who received at least one dose of either
vitamin D2 or vitamin D3 will be included in the vitamin
D2 or vitamin D3 group.
Baseline characteristics of the study population will be
summarised separately within each randomised group.
For continuous variables, means and standard deviations
will be presented, unless the variable has a highly skewed
distribution, in which case, medians, 25th and 75th per-
centiles will be presented. For categorical variables, the
number and percentage of participants within each cat-
egory will be presented. For each variable (continuous or
categorical), the percentage of missing values will be
reported. No p-values will be calculated for these tables.
The primary efficacy endpoint, HbA1c, will be compared
separately between each treatment group and placebo,
using analysis of covariance with adjustment for baseline
and centre. Where baseline values are missing, the missing
indicator method [50] will be used to enable these partici-
pants to be included in the analysis. For both vitamin D2
vs. placebo and vitamin D3 vs. placebo, the difference in
mean HbA1c, 95% confidence interval and p-value will be
reported. An analysis will be performed to check whether
adjusting for age and sex (the stratifiers) in the analysis
of covariance model has any impact on the estimated
treatment effects; if it has no impact, then they will not
be included in the model. HbA1c will be analysed and
results will be reported in IFCC units (mmol/mol), and
to enable those readers who are still using the DCCT%
units, we will also provide equivalent results using the
DCCT% units, derived using a previously described
conversion formula [51].
For each of the secondary efficacy endpoints, differences
in means (for continuous endpoints) or proportions (for
binary outcomes) between each treatment group and
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estimated using the same method described for the pri-
mary endpoint. Continuous endpoints with skewed distri-
butions will be log transformed prior to analysis, in which
case a ratio of geometric means (and confidence intervals)
will be reported.
The number and percentage of participants experien-
cing any of the safety endpoints will be reported separately
within each randomised group, without p values. For the
primary endpoint, interactions between treatment group
and baseline HbA1c, and treatment group and baseline
vitamin D will be tested by including the appropriate
interaction term in the analysis of covariance model. If the
p-value for the interaction test is <0.05, the treatment
effects and 95% confidence intervals will be estimated
within subgroups defined by levels above and below the
median value of either HbA1c or vitamin D.
For the primary efficacy endpoint, two p-values will be
calculated, one for the comparison of vitamin D2 vs pla-
cebo and one for the comparison of vitamin D3 vs placebo.
No adjustment for multiple testing will be performed. An
exploratory analysis will be performed in which mean
HbA1c will be compared between the vitamin D2 group
and the vitamin D3 group, using the same method de-
scribed above. An estimate of the difference in mean
HbA1c (adjusted for baseline), together with a 95% confi-
dence interval, will be reported. For all other efficacy end-
points, the treatment effects (vitamin D2 vs placebo and
vitamin D3 vs placebo) will be reported together with a
95% confidence interval. No p-values will be calculated.
Interpretation of results for secondary endpoints will be
cautious and results that are statistically significant in iso-
lation will be interpreted less strongly than sets of results
that are mutually supportive, or which are supported by
previous research findings.
Trial monitoring
An independent data monitoring committee (DMC) and
trial steering committee (TSC) has been set up to monitor
the trial. This consists of experts in biostatistics, diabetes,
clinical trials and biochemistry. The TSC includes a lay
member to ensure that the views of potential participants
concerning the trial design and conduct are represented.
The DMC and TSC will monitor progress of the trial, ad-
verse event data and will recommend continuation, modi-
fication or early termination of the trial. Decisions will
also be influenced by any other relevant trial data available
during the trial. No interim analysis is being planned.
Data management and quality assurance
For the Cambridge site, each participant is assigned a
unique numeric identifier at the beginning of the Fenland
Study, and a new identifier is assigned to participants
enrolled in the vitamin D supplementation trial. For theLondon site, a unique numeric identifier is assigned to
each trial participant. All personal data are stored on an
encrypted drive, and links to personal information are only
available to the study coordination team. Consent forms
and questionnaire data are stored in locked filing cabi-
nets in secure protected sites. Questionnaire data are
double entered by an independent, quality assured data-
entry company.Ethics
Ethical approval for the trial was provided by the Charing
Cross Medical Ethics Committee (reference no 09/H0711/
85; on 22nd December 2009). For the Cambridge site, full
ethical approval for the Fenland Study was obtained from
the Cambridge Local Research Ethics Committee on the
11th of May 2004 (reference number 04/Q0108/19). At
both sites, written informed consent is obtained from all
participants, and each participant’s general practitioner is
notified of their enrolment.Discussion
There is widespread interest in the potential role of vitamin
D in the prevention of diabetes and related complications,
but despite an increasing number of publications on this
topic, the potential causal association between vitamin D
and type 2 diabetes has not been confirmed. It is tantalising
to speculate that if there is a causal association the popula-
tion health impact of vitamin D supplementation could be
substantial, as we previously estimated a population attrib-
utable fraction of nearly 18% associated with 25(OH)D
levels in the insufficiency range (<50 nmol/l) [7]. Achiev-
ing and sustaining lifestyle modification for the prevention
of diabetes, though efficacious [6] is challenging, and
hence the potential role of optimal vitamin D status in re-
ducing diabetes burden is attractive.
This trial has several strengths: the inclusion of adults
from different ethnic groups, of varying ages and both
sexes, the decision to use a relatively high dose of vitamin
D supplementation at the daily equivalent dose of 3,300
IU per day that should be effective in raising 25(OH)D
levels, and the comparison of both vitamin D3 and vitamin
D2 against placebo, combined with supervised bolus dos-
ing. Following the principles of Good Clinical Practice
(GCP) we have placed participant welfare as a critical con-
sideration and have applied rigorous safety checks and ad-
verse event monitoring. We are using the well validated
and quality assured method for measuring 25(OH)D, with
tandem mass LC-MS/MS spectrometry. The secondary
endpoints will also enable the examination of assessment
of modelled cardiovascular risk, and of the feasibility and
safety of 25(OH) in relatively high doses. The limitations
of the trial merit consideration. The study sample size
allows comparison of D2 against placebo and D3 against
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lysis of D2 against D3, the study is not large enough to
address this question. The trial follow-up period is 4
months, and whilst changes in HbA1c take around 6
weeks to happen, it can be argued that the follow-up
period is too short. To mitigate this effect we are also
measuring fructosamine which is more sensitive to
changes in levels of blood glucose over a shorter period.
We are not measuring fasting glucose and insulin and
will therefore not be able to estimate insulin resistance.
This decision was made a priori, to enhance participa-
tion and is in keeping with the decision around the time
of trial inception that HbA1c can be used as a diagnostic
criterion for diabetes [52]. Finally, this trial is measuring
markers of glycaemia (e.g. HbA1c) and of cardiovascular
risk (e.g. pulse wave velocity, modelled CVD risk) with-
out ‘hard’ endpoints of incident events of diabetes or
cardiovascular disease. While the current endpoints are
important in their own right to understand the effects
of vitamin D supplementation on these parameters, and
indeed we have included adequate sample size to enable
us to investigate this appropriately, it will also be im-
portant to assess clinical events in specifically designed
future trials.
The results of this trial should contribute robust evidence
concerning whether supplementation with vitamin D
improves glycaemic markers and related metabolic
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